Latigo Biotherapeutics prices IPO at $18 per share on Nasdaq
The clinical-stage pain drug developer sold 19.2 million shares to raise about $315.7 million in net proceeds ahead of an August 10, 2026 closing.
SEC filing
Latest
Friday, August 7
BlossomHill Therapeutics prices IPO at $16.00 per share, raising $150 million
The clinical-stage oncology company will sell 9,375,000 shares on Nasdaq under the ticker BLSM, with shares expected to begin trading around August 10, 2026.
SEC filing
Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilot
AstraZeneca: Baxdrostat Phase 3 results posted, Saphnelo label updated, new China lupus trial
Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 design
Entera raised $275 million in a private placement led by BVF Partners to fund a registrational Phase 3 trial of its oral osteoporosis drug EB613 through NDA submission.
SEC filing
AbbVie registers three new trials spanning obesity, head and neck cancer, and atopic dermatitis
Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDS
Thursday, August 6
Opus Genetics reports Q2 2026 results, cites September BEST1 data and LCA5 dosing plan
Cash stood at $88.8 million as of June 30, 2026, with runway guidance into 2029 as multiple retinal gene therapy programs move toward clinic.
SEC filing
Cognition Therapeutics targets mid-2027 start for DLB psychosis Phase 3
The company said FDA talks clarified elements of the planned trial design, while it reported second-quarter 2026 results and a patent allowance for zervimesine.
SEC filing
Zoetis names Jay Saccaro EVP, CFO and COO, effective August 17, 2026
Wetteny Joseph, the outgoing CFO, will stay on as a special advisor to the CEO through early 2027 under a transition agreement.
SEC filing
Revelation Biosciences reports Q2 2026 results, advances AKI trial prep
The company said start-up activities for its Phase 2/3 acute kidney injury trial of Gemini continue, with enrollment targeted to begin by year-end.
SEC filing
HCW Biologics reports $1.6 million private securities sale in SEC filing
The Miramar, Florida biotech disclosed a Regulation D offering with a first sale date of July 29, 2026, sold in full to four investors.
SEC filing
Prestige Consumer Healthcare raises fiscal 2027 outlook after two acquisitions close
The company closed the Breathe Right and LaCorium Health deals and lifted its revenue and EPS guidance for the year to account for them.
SEC filing
Cartesian reports Q2 2026 results, four clinical readouts expected within a year
Cartesian says AURORA Phase 3 data in MG are expected in early 2027, with a new in vivo partnership and $150 million credit facility extending cash runway into 2028.
SEC filing
Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on track
Enrollment continues in JANX007, JANX014, and JANX011 trials, with JANX013 still set to start clinical testing in the second half of 2026.
SEC filing
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 update
Viatris lifted full-year guidance midpoints, won FDA approval for a new contraceptive patch, and agreed to sell Tyrvaya rights to Harrow as it navigates manufacturing disruptions in India.
SEC filing
Cullinan reports Q2 2026 results, outlines T cell engager trial timelines
Cullinan says a positive FDA meeting clears the way for a registrational AML study this quarter, with cash runway into 2029.
SEC filing
SIGA reports $37 million in TPOXX sales for second quarter of 2026
SIGA said second-quarter TPOXX deliveries completed the last procurement order under its 19C contract with the U.S. strategic national stockpile.
SEC filing
Nature's Sunshine posts Q2 net sales of $117.0 million, cuts full-year sales outlook
The company also named Ruth Perkins as incoming CFO and lowered its 2026 revenue and adjusted EBITDA guidance, citing currency and China softness.
SEC filing
Lantheus posts Q2 2026 results, pulls guidance amid pending Curium merger
Lantheus reported second-quarter revenue of $388.2 million and said it is suspending its 2026 outlook as it awaits closing of its acquisition by Curium US Holdings.
SEC filing
Organogenesis files to sell up to $75 million in stock through at-the-market program
The regenerative medicine company entered an ATM sales agreement with BTIG and Citizens JMP on August 6, 2026, as shares traded near $2.37.
SEC filing
Agenus advances Phase 3 ROBBIN trial in colon cancer, backed by July financing
Agenus reported second-quarter 2026 results and said dosing in its planned Phase 3 ROBBIN trial is expected to begin in early 2027, supported by a private placement completed in July.
SEC filing
OS Therapies registers 500,000 shares for Leonite as part of debt settlement
The company will issue the shares on or about August 6, 2026 to satisfy amounts owed under a secured note issued to Leonite in June 2026.
SEC filing
Verrica reports YCANTH demand growth, sets mid-2027 wart data, secures new credit facility
Verrica posted record YCANTH dispensing volume in Q2 2026 and said its new $27.5 million credit facility could stretch cash into 2028.
SEC filing
Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 start
Climb Bio said it plans to present initial CLYM116 Phase 1 data on September 3, 2026 and expects Phase 2 dosing in IgA nephropathy to begin in the third quarter of 2026, with cash extending into the second half of 2028.
SEC filing
Cardurion registers Phase 2 CALIBRATE-HF trial of CaMKII inhibitor CRD-4730 in HFrEF
Aurinia starts PRESERVE trial combining LUPKYNIS with biologics in lupus nephritis
The Phase 4 study will test LUPKYNIS alongside belimumab, obinutuzumab or anifrolumab in about 150 patients as Aurinia reports second-quarter results and reiterates 2026 revenue guidance.
SEC filing
Sanuwave withdraws FY2026 guidance after CMS reimbursement proposal, reports Q2 results
Sanuwave pulled its full-year outlook citing Medicare payment uncertainty as Q2 revenue fell 3% to $9.7 million and system sales dropped on reimbursement pressure and a used-equipment market.
SEC filing
Organogenesis cuts 2026 revenue outlook after steep quarterly sales decline
Second-quarter revenue fell 58% amid a slower-than-expected market recovery, prompting a lower full-year guidance range and continued cash burn.
SEC filing
Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment target
The company said its Phase 3 TEBE-AM trial is nearing its 540-patient enrollment target, with topline data possible by the end of 2026.
SEC filing
Avalo reports Q2 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027
Avalo also detailed a new anti-IL-1β antibody, AVTX-010, with an IND filing targeted for the first half of 2027, and reported $472.2 million in cash.
SEC filing
Arcturus reports Q2 2026 results, regains KOSTAIVE rights from CSL Seqirus
Company says Phase 3 decision on cystic fibrosis candidate ARCT-032 is expected in Q4 2026, while ARCT-810 dosing has finished with data due later this quarter.
SEC filing
Tiziana CEO Elrifi buys more shares on two dates in August 2026
Tiziana Life Sciences said CEO Ivor Elrifi bought company stock on Nasdaq on August 4 and August 6, 2026, each time at $1.00 per share.
SEC filing (2)
Lexicon completes SONATA-HCM enrollment, keeps Q1 2027 data timeline
The company also flagged a fourth-quarter 2026 NDA resubmission for Zynquista and reported $190.6 million in cash and investments as of June 30, 2026.
SEC filing
Aligos reports Q2 2026 results, pevifoscorvir sodium enrollment complete
Aligos said its Phase 2 B-SUPREME study of pevifoscorvir sodium has finished enrolling patients, with topline data expected in late Q3 2027, as partner Amoytop advances an HBV antisense program in China.
SEC filing
Regenxbio reports Q2 2026 results, cites Duchenne trial win and new AbbVie funds
The company raised over $200 million in July, including a $100 million AbbVie milestone, and reaffirmed 2026-2027 timelines for RGX-202, sura-vec and RGX-121.
SEC filing
CG Oncology expands stock sale program to $1.05 billion
The company filed an amendment lifting its at-the-market offering capacity by $500 million after selling $550 million in shares under the original agreement.
SEC filing
Lyell reports Q2 2026 results, updated ronde-cel and LYL273 data
Lyell says its PiNACLE trial in LBCL remains on track and reports the amendment of its LYL273 mCRC study to a Phase 1/2 design after new safety data.
SEC filing
Whitehawk reports Q2 2026 results, HWK-206 trial on track for Q3 start
Two Phase 1 studies continue enrolling and cash of $190.0 million is expected to fund operations into 2H 2028, the company said.
SEC filing
Two new trials registered: TAVI closure device study and aldosterone signaling review
Tarsus Pharmaceuticals prices $125 million private placement financing
The company said the oversubscribed PIPE deal drew existing Alkeus Pharmaceuticals investors after Tarsus announced its planned acquisition of Alkeus.
SEC filing
Evommune reports Q2 2026 results, sets EVO756 AD data for September
The company also discontinued EVO756 development in chronic spontaneous urticaria and pointed to cash lasting through 2028.
SEC filing
Xeris reports second-quarter 2026 results, tightens full-year revenue guidance
The company posted 34% year-over-year growth in net product revenue, driven by Recorlev, and narrowed its 2026 revenue outlook to $385 million to $390 million.
SEC filing
Sionna keeps two CF trial readouts on track for summer 2026
Sionna Therapeutics says its Phase 2a trial of SION-719 and its Phase 1 dual-combination trial with SION-451 both remain on schedule to deliver topline data this summer.
SEC filing
Tarsus posts record XDEMVY sales, raises guidance, moves to acquire Alkeus
Tarsus reported $173.9 million in second quarter XDEMVY sales and disclosed a pending acquisition of Alkeus Pharmaceuticals along with a $125 million private placement.
SEC filing
Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumors
BioLife Solutions posts Q2 2026 results as Repligen acquisition heads toward Q4 close
BioLife reported 21% revenue growth and a GAAP net income boosted by a tax benefit while confirming its pending sale to Repligen is expected to close in the fourth quarter of 2026.
SEC filing
Trevi starts Phase 3 OCEAN-1 and Phase 2b LAKE trials for Haduvio
Trevi Therapeutics reported second-quarter 2026 results, with cash and securities of $318.9 million and a cash runway extended into 2030.
SEC filing
Geron reports Q2 2026 results as RYTELO revenue climbs to $57.5 million
The company reiterated its full-year revenue and expense guidance while highlighting new real-world and Phase 2 myelofibrosis data and progress on its Phase 3 IMpactMF trial.
SEC filing